Publicaciones

Profesor

Toshio Miyata

 M.D., Ph.D.

 

 

The Science News (1ro de Enero, 2013)

Afiliación

Vice Presidente Ejecutivo Asociado de la Universidad de Tohoku
Asesor ejecutivo del decano de la Universidad de Tohoku Cargos actuales

Miembro de la Real academia de medicina en Bélgica (2004-presente)
Miembro del Comité ejecutivo de la Sociedad internacional de nefrología (2013)
Presidente de “Fortaleciendo la sociedad entre JSN y ISN, Sociedad japonesa de nefrología (2008’2010)

Profesor adjunto de la Facultad de Medicina Feinberg, Universidad de North Western(2012- presente)

 

Biografía

El profesor Miyata nació en Japón en el año 1961. Obtuvo los títulos de M.D y Ph.D en la Universidad de Nagoya en los años 1986 y 1991, respectivamente. Es miembro permanente de la Real Academia de Medicina en Bélgica, miembro del comité ejecutivo y asesor en la Sociedad Internacional de Nefrología (ISN), presidente del comité “Fortaleciendo la sociedad entre  JSN y ISN de la sociedad japonesa de nefrologia (JSN).
Entre las 250 publicaciones en inglés se pueden destacar la identificación de genes en desórdenes moleculares de varias enfermedades hereditarias, la delineación de mecanismos implicados en la nefropatía diabética y su prevención. También se destaca la fisiopatología de la toxicidad urémica (carbonyl stress) y su tratamiento, así como el rol de moléculas bioactivas y su inhibición (PAI-1, oxygen sensor , megsin, etc). Su laboratorio actualmente desarrolla una nueva área de investigación que combina la ciencia médica, biología estructural, química, farmacología e ingeniería en computación con el objetivo de trasladar varias moléculas que han sido identificadas, desde la investigación básica a la clínica.
Los proyectos están actualmente en la fase preclínica (PAI-1 inhibitor, Oxygen sensor inhibitor) o clínica IIa (carbonyl stress inhibitor)

 

Premiaciones

Sociedad japonesa de medicina molecular (2002)
Fundación japonesa para la salud y envejecimiento (2001)
Premio Oshima de la Sociedad japonesa de nefrologia (1995)
Premio al investigador joven de la Sociedad japonesa de medicina interna (1993)
Premio Nagoya memorial (1991)  

Publicaciones

Pyridoxamine: A novel treatment for schizophrenia with enhanced carbonyl stress.Itokawa M, Miyashita M, Arai M, Dan T, Takahashi K, Tokunaga T, Ishimoto K, Toriumi K, Ichikawa T, Horiuchi Y, Kobori A, Usami S, Yoshikawa T, Amano N, Washizuka S, Okazaki Y, Miyata T.

Psychiatry Clin Neurosci. 2018;72(1):35-44.

Pyridoxamine A novel treatment for schiz
PDFファイル 734.9 KB

A null mutation in SERPINE1 protects against biological aging in humans.Khan SS, Shah SJ,Klyachko E, Baldridge AS, Eren M, Place AT, Aviv A, Puterman E, Lloyd-Jones DM, Heiman M, Miyata T, Gupta S, Shapiro AD, Vaughan DE.

Science Advances.2017;3:eaao1617.

Science Advances 2017 3eaao1617.pdf
PDFファイル 1.7 MB

TGF-β-induced intracellular PAI-1 is responsible for retaining   hematopoietic stem cells in the niche.

Yahata T, Ibrahim A, Muguruma Y, Eren M, Shaffer AM, Watanabe N, Kaneko S, Nakabayashi N, Dan T,   Hirayama N, Vaughan DE, Miyata T, Ando K.

Blood.2017;130(21):2283-2294.

2283.full.pdf
PDFファイル 1.8 MB

 PAI-1 is a critical regulator of FGF23 homeostasis.

Eren M, Place AT, Thomas PM, Flevaris P, Miyata T, Vaughan DE.

Science Advances.2017;3: e1603259

Science FGF23.pdf
PDFファイル 772.7 KB

Plasminogen activator inhibitor-1 regulates macrophage-dependent postoperative adhesion by enhancing EGF-HER1 signaling in mice.

Honjo T, Munakata S, Tashiro Y, Salama Y, Shimazu H, Eiamboonsert S, Dhahri D, Ichimura A, Dan T, Miyata T, Takeda K, Sakamoto K, Hattori K, Heissig B.

The FASEB Journal.2017 ;31:2625-2637

FASEB J-2017-Honjo-fj.201600871RR.pdf
PDFファイル 6.4 MB

A small molecule inhibitor of PAI-1 protects against Doxorubicin-induced cellular senescence: molecular basis.

Ghosh AK, Rai R, Park KE, Eren M, Miyata T, Wilsbacher LD, Vaughan DE.

Oncotarget.2016; 7:72443-72457

oncotarget.pdf
PDFファイル 1.5 MB

 

Therapeutic potential of an orally effective small molecule inhibitor of plasminogen activator inhibitor for asthma.

Liu RM, Eldridge S, Watanabe N, Deshane J, Kuo HC, Jiang C, Wang Y, Liu G, Schwiebert L, Miyata T, Thannickal VJ.

Am J Physiol Lung Cell Mol Physiol.2016; 15: 328-336.

Am J Physiol Lung Cell Mol Physio 2016 1
PDFファイル 1.2 MB

 

Novel Plasminogen Activator Inhibitor-1 Inhibitors Prevent Diabetic Kidney Injury in a Mouse Model.

Jeong BY, Uddin MJ, Park JH, Lee JH, Lee HB, Miyata T, Ha H.

PLoS One.2016; 11: e0157012.

Plos one 2016 11 e0157012.pdf
PDFファイル 3.2 MB

 

A novel plasminogen activator inhibitor-1 inhibitor, TM5441, protects against high-fat diet-induced obesity and adipocyte injury in mice.

Piao L,Jung I, Huh JY, Miyata T, Ha H.

British J Pharmacology.2016; 173:2622-2632.

British J Pharmacology 2016 173 2622-263
PDFファイル 1.1 MB

 

Delayed intervention with pyridoxamine improves metabolic function and prevents adipose tissue inflammation and insulin resistance in high-fat diet-induced obese mice.

Maessen DE, Brouwers O, Gaens KH, Wouters K, Cleutjens JP, Janssen BJ, Miyata T, Stehouwer CD, Schalkwijk CG.

Diabetes.2016; 65: 956-966.

No268_Diabetes 2016 65 956-966.pdf
PDFファイル 2.1 MB


Small Molecule Inhibitors of Plasminogen Activator Inhibitor-1 Elicit Anti-Tumorigenic and Anti-Angiogenic Activity.

Placencio VR, Ichimura A, Miyata T, DeClerck YA.

PLoS One.2015; 10: e0133786.

PLoS One 2015 10 e0133786.pdf
PDFファイル 3.5 MB

 

Erythropoietin Synthesis in Renal Myofibroblasts Is Restored by Activation of Hypoxia Signaling.

Souma T, Nezu M, Nakano D, Yamazaki S, Hirano I, Sekine H, Dan T, Takeda K, Fong GH, Nishiyama A, Ito S, Miyata T, Yamamoto M, Suzuki N.

J Am Soc Nephrol.2016; 27: 428-438.

J Am Soc Nephrol 2015.pdf
PDFファイル 2.5 MB


Plasminogen Activator Inhibitor-1 Antagonist TM5484 Attenuates Demyelination and Axonal Degeneration in a Mice Model of Multiple Sclerosis.

Pelisch N, Dan T, Ichimura A, Sekiguchi H, Vaughan DE, van Ypersele de Strihou C, Miyata T.

PLoS One. 2015; 10: e0124510.

PLoS One 2015 10 e0124510.pdf
PDFファイル 6.8 MB


Podocyte injury-driven intracapillary plasminogen activator inhibitor type 1 accelerates podocyte loss via beta 1 integrin endocytosis.

Kobayashi N, Ueno T, Ohashi K, Yamashita H, Takahashi Y, Sakamoto K, Manabe S, Hara S, Takashima Y, Dan T, Pastan I, Miyata T, Kurihara H, Matsusaka T, Reiser J, Nagata M.

Am J Physiol Renal Physiol.2015; 308:F614-26.

Am J Physiol Renal Physiol 2015 308 F614
PDFファイル 7.7 MB


Nitric oxide prevents alveolar senescence and emphysema in a mouse model.

Boe AE, Eren M, Morales-Nebreda L, Murphy SB, Budinger GR, Mutlu GM, Miyata T, Vaughan DE.

PLoS One. 2015; 10: e0116504

PLoS One 2015 10 e0116504..pdf
PDFファイル 565.9 KB

 

PAI-1-regulated extracellular proteolysis governs senescence and survival in Klotho mice

Eren M, Boe A, Murphy SB, Place AT,  Nagpal V, Morales-Nebreda L, Urich D, Quaggin SE, Budinger GS, Mutlu GM, Miyata T, Vaughan DE.

Proc Natl Acad Sci USA. 2014; 111: 7090-7095.

Proc Natl Acad Sci USA 2014 111 7090-70
PDFファイル 1.3 MB

 

Drug discovery in renal disease —towards a more efficient framework

Miyata T, Ando T, Hiragi H, Watanabe K, Yamamoto F, Vaughan DE, Kurokawa T, Oshima Y, van Ypersele de Strihou C, Takeuchi M.

Nat Rev Nephrol. 2014; 10: 290-296.

Nat Rev Nephrol 2014 10 290-296..pdf
PDFファイル 759.2 KB

 

Inhibition of Plasminogen Activator Inhibitor Type-1 Activity Enhances Rapid and Sustainable Hematopoietic Regeneration

Ibrahim A.A, Yahata T, Onizuka M, Dan T, van Ypersele de Strihou C, Miyata T, Ando K.

Stem Cells 2014; 32: 946-958.

Stem Cells 2014 32 946-58..pdf
PDFファイル 856.8 KB

 

Glyoxalase-1 overexpression reduces endothelial dysfunction and attenuates early renal impairment in a rat model of diabetes
Brouwers O, Niessen PM, Miyata T, Østergaard JA, Flyvbjerg A, Peutz-Kootstra CJ, Sieber J, Mundel PH, Brownlee M, Janssen BJ, De Mey JG, Stehouwer CD, Schalkwijk CG.
Diabetologia 2014; 57: 224-235.

Diabetologia 2014 57 224-235..pdf
PDFファイル 620.5 KB

 

The PAI-1 antagonist TM5441 attenuates L-NAME-induced hypertension and vascular senescence
Boe A, Eren M, Murphy S, Kamide1 C, Ichimura A, Terry D, McAnally D, Smith LH, Miyata T, Vaughan DE.
Circulation 2013; 128: 2318-2324.

Circulation 2013 128 2318-2324..pdf
PDFファイル 1.1 MB

 

Kidney failure: aims for the next 10 years and barriers to success
Remuzzi G, Benigni A, Finkelstein FO, Grunfeld JP, Joly D, Katz I, Liu ZH, Miyata T, Perico N, Rodriguez-Iturbe B, Antiga L, Schaefer F, Schieppati A, Schrier RW, Tonelli M.
Lancet 2013; 382: 353-362.

Lancet 2013 382 353-362..pdf
PDFファイル 5.9 MB

 

Diabetic nephropathy: Are there new and potentially promising therapies targeting oxygen biology?

Miyata T, Suzuki N, van Ypersele de Strihou C.

Kidney Int 2013; 84: 693-702.

Kidney Int 2013 84 693-702..pdf
PDFファイル 1.2 MB

 

A Small Molecule Inhibitor to Plasminogen Activator Inhibitor 1 Inhibits Macrophage Migration

Ichimura A, Matsumoto S, Suzuki S, Dan T, Yamaki S, Sato Y, Kiyomoto H, Ishii N, Okada K, Matsuo O, Hou FF, Vaughan DE, van Ypersele de Strihou C, Miyata T.

Arterioscler Thromb Vasc Biol. 2013; 33: 935-942.

Arterioscler Thromb Vasc Biol 2013 935-
PDFファイル 2.2 MB

 

Metabolic stress response implicated in diabetic retinopathy:the role of calpain, and the therapeutic impact of calpain inhibitor.

Shanab AY, Nakazawa T, Ryu M, Tanaka Y, Himori N, Taguchi K, Yasuda M, Watanabe R, Takano J, Takaomi S, Minegishi N, Miyata T, Abe T, Yamamoto M.

Neurobiology of Disease 2012; 48: 556-567.

Neurobiology of Disease 2012;48.556-567.
PDFファイル 2.1 MB

 

The receptor of advanced glycation end products plays a central role in advanced oxidation protein products-induced podocyte apoptosis.

Zhou LL, Cao W, Xie C, Tian J, Zhou Z, Zhou Q, Zhu P, Li A, Liu Y, Miyata T, Hou FF, Nie J.

Kidney Int 2012; 82: 759-770.

Kidney Int 2012;82.759-770.pdf
PDFファイル 527.3 KB

 

Inhibition of PAI-1 induces neutrophil-driven neoangiogenesis and promotes tissue regeneration via production of angiocrine factors in mice.

Tashiro Y, Nishida C, Sato-Kusubata K, Ohki-Koizumi M, Ishihara M, Sato A, Gritli I, Komiyama H, Sato Y, Dan T, Miyata T, Okumura K, Tomiki Y, Sakamoto K, Nakauchi H, Heissig B, Hattori K.

Blood 2012; 119: 6382-6393.

Blood 2012;119.6382-6393.pdf
PDFファイル 940.1 KB

 

Protection against methylglyoxal-derived AGEs by regulation of glyoxalse-1 prevents retinal neuroglial and vasodegenerative pathology.

Berner AK, Brouwers O, Pringle R, Klaassen I, Colhoun L, McVicar C, Brockbank S, Curry JW, Miyata T, Brownlee M, Schlingemann RO, Schalkwijk C, Stitt AW. Diabetologia 2012; 55: 845-854.

Diabetologia 2012;55.845-854.pdf
PDFファイル 579.5 KB

 

Skin advanced glycation end product accumulation is negatively associated with calcaneal osteo-sono assessment index among non-diabetic adult Japanese men.
Momma H, Niu K, Kobayashi Y, Guan L, Sato M, Guo H, Chujo M, Otomo A, Yufei C, Tadaura H, Saito T, Mori T, Miyata T, Nagatomi R.

Osteoporos Int 2012; 23: 1673-1681.

Osteoporos Int 2012;23.1673-1681.pdf
PDFファイル 396.7 KB

 

Therapeutic value of small molecule inhibitor to plasminogen activator inhibitor-1 for lung fibrosis.

Huang WT, Vayalil PK, Miyata T, Hagood J, Liu RM.

Am J Respir Cell Mol Biol. 2012; 46: 87-95.

Am J Respir Cell Mol Biol 2012;46.87-95.
PDFファイル 1.7 MB

 

Glyoxalase I retards renal senescence.

Ikeda Y, Inagi R, Miyata T, Nagai R, Arai M, Miyashita M, Itokawa M, Fujita T, Nangaku M.

Am J Pathol 2011; 179: 2810-2821.

Am J Pathol 2011;179.2810-2821.pdf
PDFファイル 2.7 MB

 

New era for drug discovery and development in renal disease.

  Miyata T, Kikuchi K, Kiyomoyo H,van Ypersele de Strihou C.

  Nat Rev Nephrol 2011;7:469-477.

Nat Rev Nephrol. 2011;7.469-477.pdf
PDFファイル 761.1 KB

 

In Oxidative Stress in Applied Basic Research and Clinical Practice: Studies on Renal Disorders (Springer),

edited by Toshio MIyata, Kai-Uwe Eckardt, Masaomi Nangaku.

Studies on Renal Disorders.pdf
PDFファイル 75.6 KB

 

Hypoxia. 1. Intracellular sensors for oxygen and oxidative stress: novel therapeutic targets.

Miyata T, Takizawa S,van Ypersele de Strihou C.

Am J Physiol Cell Physiol 2011;300:226-231.

Am J Physiol Cell Physiol 2011;300.226-2
PDFファイル 605.0 KB

 

Effect of Sevelamer and Calcium-Based Phosphate Binders on Coronary Artery Calcification and Accumulation of Circulating Advanced Glycation End Products in Hemodialysis Patients.

Kakuta T, Tanaka R, Hyodo T, Suzuki H, Kanai G, Nagaoka M, Takahashi H, Hirawa N, Oogushi Y, Miyata T, Kobayashi H, Fukagawa M, Saito A.

Am J Kidney Dis 2011;57:422-431.

Am J Kidney Dis 2011;57.422-431.pdf
PDFファイル 1.4 MB

 

Overexpression of Glyoxalase-I Reduces Hyperglycemia–induced Levels of Advanced Glycation Endproducts and Oxidative Stress in Diabetic Rats.

Brouwers O, Niessen PM, Ferreira I, Miyata T, Scheffer PG, Teerlink T, Schrauwen P, Brownlee M, Stehouwer CD, Schalkwijk CG.

J Biol Chem. 2011 ;286:1374-1380.

J Biol Chem. 2011;286.1374-1380.pdf
PDFファイル 1.1 MB

 

Enhanced carbonyl stress in a subpopulation of schizophrenia.

Arai M, Yuzawa H, Nohara I, Ohnishi T, Obata N, Iwayama Y, Haga S, Toyota T, Ujike H, Arai M, Ichikawa T, Nishida A,Tanaka Y, Furukawa A, Aikawa Y, Kuroda O, Niizato K, Izawa R, Nakamura K, Mori N, Matsuzawa D, Hashimoto K, Iyo M, Sora I, Matsushita M, Okazaki Y, Yoshikawa T, Miyata T, Itokawa M.

Arch Gen Psychiatry 2010; 67: 589-597.

Arch Gen Psychiatry 2010;67.589-597.pdf
PDFファイル 180.3 KB

 

Diabetic nephropathy: a disorder of oxygen metabolism?

Miyata T, van Ypersele de Strihou C.

Nat Rev Nephrol. 2010;6:83-95.

Nat Rev Nephrol. 2010;6.83-95.pdf
PDFファイル 707.1 KB

 

Por favor haga referencia a lo siguiente para los detalles.

 URL: http://www.researcherid.com/rid/A-4872-2010